Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Science (New York, N.Y.)|June 27, 2024
Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editorEdwin N Neumann, Tessa M Bertozzi, Elaine Wu, et al.
Neurology|June 19, 2024
Fluid Biomarkers in Individuals at Risk for Genetic Prion Disease up to Disease ConversionSonia M Vallabh, Meredith A Mortberg, Shona W Allen, et al.
BMC Medicine|June 20, 2020
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion diseaseSonia M Vallabh, Eric Vallabh Minikel, Victoria J Williams, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
PrP turnover in vivo and the time to effect of prion disease therapeuticsTaylor L Corridon, Jill O'Moore, Yuan Lian, et al.
Medrxiv : the Preprint Server for Health Sciences|May 15, 2024
Evidence that minocycline treatment confounds the interpretation of neurofilament as a biomarkerJuliana E Gentile, Christina Heiss, Taylor L Corridon, et al.
JCI Insight|July 31, 2019
Antisense oligonucleotides extend survival of prion-infected miceGregory J Raymond, Hien Tran Zhao, Brent Race, et al.
JCI Insight|February 8, 2022
Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNSMeredith A Mortberg, Hien T Zhao, Andrew G Reidenbach, et al.
Brain Communications|May 26, 2025
Evidence that minocycline treatment confounds the interpretation of neurofilament as a biomarkerJuliana E Gentile, Christina N Heiss, Taylor L Corridon, et al.
Nucleic Acids Research|August 11, 2020
Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpointsEric Vallabh Minikel, Hien T Zhao, Jason Le, et al.
Plos Pathogens|May 26, 2026
PrP turnover in vivo and the time to effect of prion disease therapeuticsTaylor L Corridon, Jill O'Moore, Alyssa Seerley, et al.
Pageof 4